NCT07446816
Recruiting
Phase 1
A Phase Ib Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 in Patients With Advanced Solid Tumours
Ganzhou Hemay Pharmaceutical Co., Ltd1 site in 1 country24 target enrollmentStarted: December 3, 2025Last updated:
InterventionsHemay181
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Efficacy indicators
Overview
Brief Summary
An open-label phase I clinical study,which enrolled subjects with advanced solid tumors who have failed to respond to adequate standard therapies or have no available effective standard therapy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects who voluntarily signed a written informed consent form before the start of the study;
- •Subjects who have pathologically (histologically or cytologically) confirmed advanced solid tumorsand have failed to respond to adequate standard therapies or currently have no available effective standard therapy .
- •Subjects who have a least one measurable lesion that can be evaluated by CT/MRI and meets the requirement for reproducible evaluation in RECIST V1.1;
- •At least 4 weeks or 5 half-lives (whichever is longer) following the most recent treatment (chemotherapy, targeted therapy, immunotherapy, radiotherapy, and/or major surgery), with recovery from treatment-induced adverse reactions to ≤ Grade 1 (CTCAE Version 5.0) \[Patients with alopecia (any grade), hyperpigmentation (any grade), or peripheral sensory neuropathy (≤ Grade 2) may be included\].
- •Subjects with ECOG PS score of 0-1;
- •Subjects with expected survival more than 3 months;
- •Women of childbearing potential (including partners) who are not planning to become pregnant and who voluntarily take effective contraceptive measures from signing the informed consent form until 6 months after the last dose in the study;
Exclusion Criteria
- •Women during pregnancy or breastfeeding;
- •HIV test positive; syphilis test positive; hepatitis B surface antigen positive with HBV-DNA exceeding the upper limit of normal; hepatitis C virus (HCV) antibody positive with HCV-RNA exceeding the upper limit of normal;
- •Having received drug treatment from another clinical trial within the four weeks prior to enrolment;
- •Aallergy to the active ingredient or excipients of the investigational medicinal product;
- •Patients with a history of alcohol or drug abuse or dependence, or a history of severe mental illness;
- •The investigator considers the subject to be unsuitable for participation in this clinical trial due to any clinical or laboratory abnormalities.
Arms & Interventions
Experimental group
Experimental
Intravenous infusion, Once per treatment cycle
Intervention: Hemay181 (Drug)
Outcomes
Primary Outcomes
Efficacy indicators
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Objective response rate (ORR)
Secondary Outcomes
- Safety indicators(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
A Phase 1 Study of HDM2017 in Advanced Solid TumorsNCT07274085Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.96
Not yet recruiting
Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesNCT07415031Mirati Therapeutics Inc.170
Recruiting
Not Applicable
VSV-02 Compassionate Use in Advanced Solid TumorsNCT07260591The First Affiliated Hospital of Xinxiang Medical College6
Not yet recruiting
Not Applicable
SKB500 Combinations in Patients With Small Cell Lung CancerNCT07296809Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.80
Recruiting
Phase 1/2
A Clinical Trial for Patients with Advanced Cancers2024-515020-36-00Corbus Pharmaceuticals Inc.108